|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Kissei Pharmaceutical Co., Ltd. and Eisai Company, Ltd. (ESALY.PK) Sign a License Agreement to Develop and Commercialize Glufast(R), a Rapid-acting Insulin Secretagogue in 10 ASEAN Countries
6/13/2007 1:14:56 PM
Tokyo, June 12, 2007 (JCN Newswire) - Kissei Pharmaceutical Co., Ltd. and Eisai Co., Ltd. announced the conclusion of a license agreement for Glufast(R) (tablets, generic name: mitiglinide calcium hydrate), a rapid-acting insulin secretagogue originally created and developed by Kissei. In this agreement, Eisai gained the exclusive development and commercialization rights of Glufast(R) in a total of 10 ASEAN countries from Kissei.
|
|
|
|
|
|
|
|
|
|
|